Abbott India Valuation

Is 500488 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 500488 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 500488 (₹27481.6) is trading above our estimate of fair value (₹11114.26)

Significantly Below Fair Value: 500488 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 500488?

Other financial metrics that can be useful for relative valuation.

500488 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue9.8x
Enterprise Value/EBITDA39.3x
PEG Ratio4.8x

Price to Earnings Ratio vs Peers

How does 500488's PE Ratio compare to its peers?

The above table shows the PE ratio for 500488 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.7x
ALKEM Alkem Laboratories
34.6x13.7%₹621.7b
500257 Lupin
42.8x18.6%₹828.4b
AUROPHARMA Aurobindo Pharma
24.5x13.6%₹772.2b
MANKIND Mankind Pharma
45.1x15.8%₹848.2b
500488 Abbott India
48.6x10.2%₹591.2b

Price-To-Earnings vs Peers: 500488 is expensive based on its Price-To-Earnings Ratio (48.6x) compared to the peer average (36.7x).


Price to Earnings Ratio vs Industry

How does 500488's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.2%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.2%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 500488 is expensive based on its Price-To-Earnings Ratio (48.6x) compared to the Indian Pharmaceuticals industry average (34.6x).


Price to Earnings Ratio vs Fair Ratio

What is 500488's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

500488 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio48.6x
Fair PE Ratio35.7x

Price-To-Earnings vs Fair Ratio: 500488 is expensive based on its Price-To-Earnings Ratio (48.6x) compared to the estimated Fair Price-To-Earnings Ratio (35.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 500488 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹27,481.60
₹27,670.43
+0.7%
16.5%₹32,500.00₹17,872.00n/a7
Jul ’25₹27,610.75
₹27,670.43
+0.2%
16.5%₹32,500.00₹17,872.00n/a7
Jun ’25₹25,875.95
₹27,670.43
+6.9%
16.5%₹32,500.00₹17,872.00n/a7
May ’25₹26,415.75
₹27,670.43
+4.7%
16.6%₹33,000.00₹17,872.00n/a7
Apr ’25₹27,508.30
₹27,241.86
-1.0%
18.2%₹33,000.00₹17,872.00n/a7
Mar ’25₹28,215.00
₹26,338.25
-6.7%
19.8%₹33,000.00₹17,872.00n/a8
Feb ’25₹25,917.10
₹25,056.44
-3.3%
15.5%₹29,500.00₹17,872.00n/a9
Jan ’25₹22,731.20
₹24,752.33
+8.9%
13.4%₹29,200.00₹20,013.00n/a9
Dec ’24₹23,675.70
₹24,752.33
+4.5%
13.4%₹29,200.00₹20,013.00n/a9
Nov ’24₹22,232.85
₹23,868.33
+7.4%
12.5%₹28,300.00₹19,777.00n/a9
Oct ’24₹23,159.10
₹23,558.13
+1.7%
13.5%₹28,300.00₹19,700.00n/a8
Sep ’24₹22,713.95
₹23,558.13
+3.7%
13.5%₹28,300.00₹19,700.00n/a8
Aug ’24₹23,934.20
₹23,005.00
-3.9%
10.9%₹26,800.00₹19,700.00n/a9
Jul ’24₹23,414.70
₹21,850.25
-6.7%
18.9%₹26,800.00₹12,700.00₹27,610.758
Jun ’24₹21,596.45
₹22,006.50
+1.9%
18.6%₹26,800.00₹12,700.00₹25,875.958
May ’24₹22,291.30
₹20,934.50
-6.1%
17.4%₹26,200.00₹12,700.00₹26,415.758
Apr ’24₹22,086.55
₹20,715.75
-6.2%
16.2%₹24,450.00₹12,700.00₹27,508.308
Mar ’24₹20,467.60
₹20,945.11
+2.3%
15.4%₹24,450.00₹12,700.00₹28,215.009
Feb ’24₹20,698.40
₹21,150.67
+2.2%
16.6%₹26,500.00₹12,700.00₹25,917.109
Jan ’24₹21,431.10
₹20,432.22
-4.7%
16.3%₹23,100.00₹12,700.00₹22,731.209
Dec ’23₹20,542.15
₹20,432.22
-0.5%
16.3%₹23,100.00₹12,700.00₹23,675.709
Nov ’23₹19,656.75
₹19,971.11
+1.6%
15.7%₹22,780.00₹12,700.00₹22,232.859
Oct ’23₹19,121.50
₹19,971.11
+4.4%
15.7%₹22,780.00₹12,700.00₹23,159.109
Sep ’23₹18,461.45
₹19,971.11
+8.2%
15.7%₹22,780.00₹12,700.00₹22,713.959
Aug ’23₹20,541.95
₹19,714.78
-4.0%
15.8%₹22,800.00₹12,700.00₹23,934.209
Jul ’23₹19,081.95
₹19,329.13
+1.3%
16.0%₹22,780.00₹12,700.00₹23,414.708

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.